Com. v. Perralta, E.

CourtSuperior Court of Pennsylvania
DecidedOctober 21, 2024
Docket690 MDA 2023
StatusUnpublished

This text of Com. v. Perralta, E. (Com. v. Perralta, E.) is published on Counsel Stack Legal Research, covering Superior Court of Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Com. v. Perralta, E., (Pa. Ct. App. 2024).

Opinion

J-S19036-24

NON-PRECEDENTIAL DECISION - SEE SUPERIOR COURT O.P. 65.37

COMMONWEALTH OF PENNSYLVANIA : IN THE SUPERIOR COURT OF : PENNSYLVANIA : v. : : : EMELIO PERRALTA : : Appellant : No. 690 MDA 2023

Appeal from the PCRA Order Entered April 19, 2023 In the Court of Common Pleas of Lancaster County Criminal Division at No(s): CP-36-CR-0001867-2020, CP-36-CR-0005261-2020, CP-36-CR-0006636-2019, CP-36-CR-0006637-2019

BEFORE: DUBOW, J., BECK, J., and COLINS, J.*

MEMORANDUM BY COLINS, J.: FILED: OCTOBER 21, 2024

Appellant, Emelio Perralta, appeals from the order of the Court of

Common Pleas of Lancaster County that denied his petition filed under the

Post Conviction Relief Act (PCRA).1 Counsel for Appellant in this appeal (PCRA

appellate counsel) has filed an application to withdraw and a brief asserting

that the appeal of the denial of Appellant’s PCRA claim has no arguable merit.

After careful review, we affirm the PCRA court’s ruling rejecting the ground

for relief litigated below by Appellant’s prior counsel (PCRA counsel) but vacate

in part its denial of the PCRA petition and remand for the PCRA court to

____________________________________________

* Retired Senior Judge assigned to the Superior Court.

1 42 Pa.C.S. §§ 9541-9546. J-S19036-24

address five claims of PCRA counsel ineffectiveness that Appellant has raised

in this appeal. Because PCRA appellate counsel has not shown that the appeal

is wholly without merit, we deny the application to withdraw.

This appeal arises from Appellant’s sale of fentanyl that caused the

November 8, 2019 death of a woman who used it (Victim), fentanyl buys from

Appellant on August 7 and September 26, 2019, and fentanyl found on

Appellant’s person when he was arrested on November 23, 2019. Appellant

was charged at separate dockets with delivery of fentanyl for the August 7,

2019 buy, delivery of fentanyl for the September 26, 2019 buy, drug delivery

resulting in death for the fentanyl sale that caused Victim’s death, and

possession with intent to deliver (PWID) for the fentanyl found on his person

when he was arrested.

On February 26, 2021, the Commonwealth filed a motion to join the four

cases for trial. Appellant's trial counsel did not oppose the motion, and the

trial court on July 20, 2021, ordered the cases consolidated for trial. A jury

trial commenced on December 6, 2021. At trial, the Commonwealth’s

evidence with respect to the drug delivery resulting in death charge showed

that Victim died from a fentanyl overdose in the morning hours of November

8, 2019, that Appellant sold fentanyl to Tyler Blantz the day before, that Blantz

shared that fentanyl with Victim, who was his girlfriend, and that Victim

injected that fentanyl the evening before her death. N.T. Trial at 231, 235-

38, 287, 289, 291-306, 325-26, 334-45, 357, 365-73, 386, 395-98. Appellant

-2- J-S19036-24

testified in his own defense at trial and testified that the only time that he

supplied drugs to Blantz was a week or two after Victim’s death. Id. at 509.

Appellant also testified that he never supplied any drugs to Victim because he

was told not to give drugs to Victim no matter how sick she claimed to be

since she had just come out of rehab. Id. at 509-10.

The trial court instructed the jury on drug delivery resulting in death as

follows:

To find the defendant guilty of [drug delivery resulting in death], you must find that the following elements have been proven beyond a reasonable doubt: First, that the defendant administered, dispensed, delivered, gave, prescribed, sold or distributed a controlled substance or a counterfeit controlled substance to a person. Second, that the defendant did so intentionally, that is, it was his conscious object to administer, dispense, deliver, give, prescribe, sell or distribut[e] a controlled substance or counterfeit controlled substance to a person. Third, that the administration, dispense, delivery, prescription or sale was in violation of the Controlled Substance, Drug, Device and Cosmetic Act. And, fourth, that a person has died as a result of using that substance. Proof of malice is not an element of that crime. If you find that each of these elements have been proven beyond a reasonable doubt, then you should find the defendant guilty. If you do not find each proven beyond a reasonable doubt, then you must find him not guilty.

N.T. Trial at 586-87. Appellant’s trial counsel did not object to that instruction

or request any additional instruction on the drug delivery resulting in death

charge. Id. at 590. On December 9, 2021, the jury convicted Appellant of

all of the charges. Id. at 596-99. On March 9, 2022, the trial court sentenced

Appellant to an aggregate term of imprisonment of 9 to 18 years’

incarceration, consisting of consecutive sentences of 6 to 12 years for the drug

-3- J-S19036-24

delivery resulting in death conviction and 3 to 6 years for PWID and concurrent

sentences of 2 to 5 years on the other charges. Sentencing Orders. Appellant

filed timely direct appeals but discontinued the appeals on April 21, 2022.

On April 29, 2022, Appellant filed a timely pro se PCRA petition asserting

multiple claims of ineffective assistance of trial counsel, including claims that

his trial counsel was ineffective for failing to object to the trial court’s jury

instruction on the drug delivery resulting in death charge and for failing to

challenge the consolidation of the cases, and the PCRA court appointed PCRA

counsel for Appellant. On July 20, 2022, PCRA counsel filed an amended PCRA

petition that asserted two claims for relief: (1) that trial counsel was

ineffective for failing to object to the trial court’s omission in its drug delivery

resulting in death instruction of the mens rea of recklessness that the

Commonwealth must prove with respect to causation of the death and (2) that

trial counsel was ineffective for failing to move to sever the cases.

On January 3, 2023, the PCRA court held a hearing on the amended

PCRA petition at which Appellant’s trial counsel and Appellant testified. At the

start of the hearing, PCRA counsel advised the court that he was withdrawing

the claim trial counsel was ineffective for failing to seek severance and that

only Appellant’s claim of ineffectiveness of trial counsel with respect to the

jury instruction on drug delivery resulting in death would be addressed at the

hearing. N.T. PCRA at 3. Appellant’s trial counsel testified that she believed

that the trial court’s drug delivery resulting in death instruction was an

-4- J-S19036-24

accurate statement of the law because it was the standard jury instruction

and that she did not believe that there was any basis to object to the

instruction. Id. at 9, 15-16. Trial counsel testified that at the time of the

PCRA hearing she believed that the crime of drug delivery resulting in death

required that the Commonwealth prove that the defendant acted recklessly

with regard to causing the death but could not recall whether she knew that

at the time of Appellant’s trial. Id. at 12. Appellant did not testify to any

conversations with trial counsel or concerning the jury instruction but admitted

that he testified at trial that he knew not to give Victim drugs because she had

just gotten out of rehab. Id. at 23-24.

On April 19, 2023, the PCRA court denied Appellant’s PCRA petition.

PCRA Court Order, 4/19/23.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anders v. California
386 U.S. 738 (Supreme Court, 1967)
Commonwealth v. Ketterer
725 A.2d 801 (Superior Court of Pennsylvania, 1999)
Commonwealth v. McGill
832 A.2d 1014 (Supreme Court of Pennsylvania, 2003)
Commonwealth v. Turner
544 A.2d 927 (Supreme Court of Pennsylvania, 1988)
Commonwealth v. Widgins
29 A.3d 816 (Superior Court of Pennsylvania, 2011)
Commonwealth v. Humpheys
532 A.2d 836 (Supreme Court of Pennsylvania, 1987)
Commonwealth v. Moran, Aplt
104 A.3d 1136 (Supreme Court of Pennsylvania, 2014)
Commonwealth v. Freeland
106 A.3d 768 (Superior Court of Pennsylvania, 2014)
Commonwealth v. Eichinger, J., Aplt
108 A.3d 821 (Supreme Court of Pennsylvania, 2014)
Commonwealth v. Kakhankham
132 A.3d 986 (Superior Court of Pennsylvania, 2015)
Commonwealth v. Mason, L., Aplt
130 A.3d 601 (Supreme Court of Pennsylvania, 2015)
Commonwealth v. Walters
135 A.3d 589 (Superior Court of Pennsylvania, 2016)
Commonwealth v. Storey
167 A.3d 750 (Superior Court of Pennsylvania, 2017)
Commonwealth, Aplt. v. Montalvo, M.
205 A.3d 274 (Supreme Court of Pennsylvania, 2019)
Commonwealth v. Nichols
692 A.2d 181 (Superior Court of Pennsylvania, 1997)
Commonwealth v. Doty
48 A.3d 451 (Superior Court of Pennsylvania, 2012)
Commonwealth v. Stewart
84 A.3d 701 (Superior Court of Pennsylvania, 2013)
Commonwealth v. Safrit
538 A.2d 1335 (Supreme Court of Pennsylvania, 1988)
Commonwealth v. Jones
210 A.3d 1014 (Supreme Court of Pennsylvania, 2019)
Com. v. Scott, J.
2024 Pa. Super. 232 (Superior Court of Pennsylvania, 2024)

Cite This Page — Counsel Stack

Bluebook (online)
Com. v. Perralta, E., Counsel Stack Legal Research, https://law.counselstack.com/opinion/com-v-perralta-e-pasuperct-2024.